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Somatic cells show a spontaneous decline in growth rate in continuous culture. This is not related to elapsed time but to an
increasing number of population doublings, eventually terminating in a quiescent but viable state termed replicative senescence.
These cells are commonly multinucleated and do not respond to mitogens or apoptotic stimuli. Cells displaying characteristics
of senescent cells can also be observed in response to other stimuli, such as oncogenic stress, DNA damage, or cytotoxic drugs
and have been reported to be found in vivo. Most tumors show unlimited replicative potential, leading to the hypothesis that
cellular senescence is a natural antitumor program. Recent findings suggest that cellular senescence is a natural mechanism to
prevent undesired oncogenic stress in somatic cells that has been lost in malignant tumors. Given that the ultimate goal of cancer
research is to find the definitive cure for as many tumor types as possible, exploration of cellular senescence to drive towards
antitumor therapies may decisively influence the outcome of new drugs. In the present paper, we will review the potential of
cellular senescence to be used as target for anticancer therapy.
1. The Biology of Senescence
Over 40 years ago, Hayflick [1] established that human
diploid fibroblasts show a spontaneous decline in growth
rate in continuous culture related not to elapsed time but
to an increasing number of population doublings, eventually
terminating in a quiescent but viable state now known
as replicative senescence. These cells show a flat, enlarged
morphology with low pH β-gal activity, are commonly mult-
inucleated, and are irresponsive to mitogens or apoptotic
stimuli. Similar behaviour has since then been observed
in a wide variety of normal cells, and it is now widely
accepted [2] that normal human somatic cells have an
intrinsically limited proliferative lifespan, even under ideal
growth conditions. Moreover, the senescent phenotype is
associated with a typical gene-expression profile [3–5]. Cells
displaying characteristics of senescent cells, however, can be
observed in response to other stimuli, such as oncogenic
stress, DNA damage, or cytotoxic drugs [6].
Cells displaying senescent characteristics have not only
been observed in cell culture but also in their maternal tissue
environment. A number of reports have related reduced
cellular lifespan with metabolic disease, stress sensitivity,
progeria syndromes, and impaired healing, indicating that
entry into cellular senescence may contribute to human
disease. Indeed, it has been suggested that cellular senescence
is in part responsible for the pathogenesis of a number of
human diseases, such as atherosclerosis, osteoarthritis, mus-
cular degeneration, ulcer formation, Alzheimer’s dementia,
diabetes, and immune exhaustion.
Most cancers contain cell populations that have escaped
the normal limitations on proliferative potential. This capa-
bility, known as immortality, contrasts with the limited
lifespan of normal somatic cells. It has therefore been pro-
posed that cellular senescence is a major tumor suppressor
mechanism thatmust be overcome during tumorigenesis [2].
The kinetics of replicative senescence do not show an
abrupt arrest of the whole population, but a gradual decline
in the proportion of dividing cells [7], the exact timing of
which varies between both cell types and sister clones [8].
This behaviour is best explained as the result of (i) an intrin-
sic control mechanism linked to elapsed cell divisions—the
senescence clock—which progressively desensitises the cell-
cycle machinery to growth factor stimulation, together with
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(ii) a stochastic component probably having the same (still
unknown) basis as that observed in immortal cells under
conditions of growth factor restriction. Stem cells can give
rise to diﬀerentiated progeny and are capable of autorenewal.
In some renewing tissues, stem cells undergo more than
1000 divisions in a lifetime with no morphological signs of
senescence [8]. This indicates that at a certain point of lineage
diﬀerentiation, cells activate the senescence clock that ulti-
mately induces cell senescence through a series of eﬀectors.
More recently, the finite number of divisions—referred
to as the “Hayflick limit”—was attributed to the progressive
shortening of chromosomal ends. Telomere shortening is
considered to be the most probable molecular mechanism
explaining the existence of such a senescence clock control-
ling replicative senescence [9, 10]. Eukaryotic cells cannot
replicate the very ends of their chromosomes, the telomeres,
resulting in shortening their lengths with every cell division
until they reach a critical threshold, at which point cells
stop replicating [11]. However, enforced replication despite
short telomeres ends in high chromosomal instability
and apoptosis, a process known as crisis. Many other
mechanisms, however, have been also proposed (Table 1).
Senescent cells display molecular markers characteristics
of cells bearing double-strand breaks. These markers include
nuclear foci of phosphorylated histone H2AX and the
localization at double-strand break sites of DNA-repair and
DNA-damage checkpoint factors, such as 53BP1,MDC1, and
NBS1 [12, 13]. Senescent cells also contain activated forms of
the DNA-damage checkpoint kinases Chk1 and Chk2. These
and other results suggest that telomere shortening initiates
senescence trough a DNA-damage response. This will explain
why other DNA-damaging stresses, such as culture shock,
might initiate senescence without telomere involvement.
The initiation of senescence triggers the generation and
accumulation of distinct heterochromatic structures known
as senescence associated heterochromatic foci (SAHF). The
formation of SAHF coincides with the recruitment of
heterochromatic proteins and the pRB tumor suppressor to
E2F-responsive promoters. SAHF accumulation is associated
with stable repression of E2F target genes and does not occur
in reversibly arrested cells. SAHF formation and promoter
repression depend on the integrity of the pRb pathway [14].
These results provide an explanation for the stability of the
senescent state.
Consistent with a role in aging, senescent cells accu-
mulate with age in many rodent and human tissues [15].
Moreover, they are found at sites of age-related pathology,
including degenerative disorders such as osteoarthritis and
atherosclerosis [15] and hyperproliferative lesions such as
benign prostatic hyperplasia [16] and melanocytic naevi
[17]. A limited number of cell culture and mouse xenograft
studies support the idea that senescent cells secrete factors
that can disrupt tissue structure and function and pro-
mote cancer progression [18–20]. Recent studies on the
senescence-associated secretory phenotype (SASP) of human
and mouse fibroblasts show that it is conserved across
cell types and species and that specific secreted factors are
strong candidates for stimulating malignant phenotypes in
neighboring cells [21–23].
The idea that a biological process such as cellular
senescence can be both beneficial (tumor suppressive) and
deleterious (protumorigenic) is consistent with a major
evolutionary theory of aging termed antagonistic pleiotropy
[23]. The SASP may be the major reason for the deleterious
side of the senescence response [24].
In addition to telomere dysfunction, cellular senescence
can be elicited by other types of stress, including oncogene
activation [25]. This phenomenon is not observed for onco-
genic RAS exclusively; many—but not all—of its eﬀectors,
including activated mutants of RAF, MEK, and BRAF, were
shown to cause senescence as well [26–29]. Some oncogenes,
such as RAS, CDC6, cyclin E, and STAT5 which induce
senescence also trigger a DNA-damage response (DDR),
which is associated with DNA hyperreplication and appears
to be causally involved in oncogene-induced senescence
(OIS), in vitro [30–33]. During most of the last decade,
OIS has been studied predominantly in cell culture systems,
triggering a long debate as to whether or not OIS corresponds
to a physiologically relevant phenomenon in vivo. In favour
of OIS representing an in vitro phenomenon only is that
artificial conditions, such as the use of bovine serum and
plastic dishes, as well as the presence of supraphysiologic O2,
generate a stress signal that at the very least contributes to
triggering a cellular senescence response [34, 35]. However,
conversely, senescence bypass screens have identified several
genuine human oncogenes, including TBX2, BCL6, KLF4,
hDRIL, BRF1, and PPP1CA [36]. Furthermore, virtually all
human cancers lack functional p53/pRB pathways, two key
senescence-signalling routes [37], and often carry mutations
in sets of genes, which are known to collaborate in vitro in
bypassing the senescence response.
2. Effector Pathways
Cellular senescence pathways are believed to have multiple
layers of regulation, with additional redundancy built into
these layers [38]. On the basis of the complementation
studies, there are at least four senescence genes or pathways.
There are, however, many more chromosomes that can
induce senescence than there are senescence complemen-
tation groups. Furthermore, there are some immortal cell
lines that have been assigned to multiple complementation
groups [39]. This indicates that in any one immortal cell line,
there are probably multiple senescence genes/pathways that
are abrogated [40]. Many of the functional studies, where
a putative senescence gene is overexpressed in cells, indicate
that although multiple genes/pathways may be abrogated in
a particular cell line, as little as one gene/pathway is required
for repair and subsequent reversion to senescence.
Pathways known to regulate cellular senescence/immor-
talisation, including the p16INK4a/pRB pathway, the
p19ARF/p53/p21CIP1/WAF1 pathway, and the PTEN/
p27KIP1 pathway, are reviewed in [36, 41–44]. Other genes
that have been shown to induce a senescence-like phenotype
include PPP1A [45], SAHH [46, 47], Csn2, Arase and BRF1
[48], PGM [49], IGFBP3 and IGFBPrP1 [50], PAI-1 [51, 52],
MKK3 [53], MKK6 [53, 54], Smurf2 [55], and HIC-5
[56]. All these genes have shown to be related to human
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Table 1: Cellular clock driving senescence hypothesis.
Cellular clock Cause Molecular readout
Error-catastrophe theories
Somatic mutation accumulation Metabolism/oxygen free radicals Altered protein function, DNA damage
Mitochondrial DNA mutation Oxygen free radicals Altered mitochondrial function
Posttranslational modification of proteins
Oxidation, glycosylation, acetylation,
methylation, and so forth
Altered function of proteins
Altered proteolysis Errors in proteolysis machinery Accumulation non functional proteins
Deterministic theories
Telomere shortening no replication of the telomere ends
DNA damage, exposure ends of
telomeres, Liberation regulatory
proteins, and so forth
Changes in heterochromatin domains changes in transcription
Changes in DNA methylation changes in transcription
Codon restriction
Switching codon preferences in early
development, restrict availability later In life
Altered protein synthesis
Terminal diﬀerentiation
Senescence is a form of terminal di-
ﬀerentiation genetically controlled
Several hypotheses for cellular clocks driving senescence have been proposed. Most of them lay into error-catastrophe theories, suggesting that senescence
is a byproduct of cell living, and deterministic theories, suggesting a genetic program for cellular senescence. Some of the most representative theories are
collected in this table.
tumorigenesis. However, all these genes and their pathways,
as indicated earlier, can act in sequential steps conforming a
well-regulated process.
Two major eﬀector pathways have been directly related
to senescence: the p14ARF/p53/p21 pathway and the
INK4/CDK/pRb pathway [57] (Figure 1). The absence
of p53 function induced by dominant negative mutants,
specific p53 antisense mRNA, oligonucleotides, or viral
oncoproteins (such as SV40 T antigen or HPV16 E6) is
suﬃcient to substantially extend the lifespan of several cell
types in culture [58]. Consistent with this, senescence is
associated with a switch-on of the transactivation function
of p53 in culture [59]. Coincident with telomere shortening,
DNA-damage checkpoint activation, and associated genomic
instability, p53 is also activated in vivo[60]. Deletion of p53
attenuated the cellular and organismal eﬀects of telomere
dysfunction, establishing a key role for p53 in the shortening
response [60].
Other p53 regulatory proteins are also involved in
senescence (Figure 1). MDM2 protein has p53 ubiquitin
ligase activity and forms an autoregulatory loop with p53
[61]. Overexpression of MDM2 targets p53 for degrada-
tion and induces functional-p53 loss [62]. The product
of another gene upregulated in senescence—p14ARF—can
release p53 from inhibition by MDM2 and cause growth
arrest in young fibroblasts [62]. Seeding mouse embryonic
fibroblasts (MEFs) into culture induces the synthesis of
ARF protein, which continues to accumulate until the cells
enter senescence [63]. MEFs derived from ARF-disrupted
mice [63] or wild-type fibroblasts expressing an eﬃcient
ARF antisense construct [64] are also eﬃciently immor-
talised. Concomitant with this observation, overexpression
of MDM2 in naı¨ve MEFs produces eﬃcient immortalisation
[64].
Activation of p53 induces the upregulation of the cyclin-
dependent kinase (CDK) inhibitor p21WAF1, which has a
direct inhibitory action on the cell-cycle machinery [37] and
correlates well with the declining growth rate in senescing
cultures. In mouse embryo fibroblasts, however, the absence
of p21WAF1 does not overcome senescence [65, 66]. This
suggests that at least one additional downstream eﬀector
is needed for p53-induced growth arrest in senescence. In
contrast, a diﬀerent behaviour is observed in human cells,
where elimination of p21 by a double round of homologous
recombination is suﬃcient to bypass senescence [67]. Other
p53 eﬀectors might be also involved, such as 14-3-3 and
GADD45, which inhibit G2/M transition or downregulation
of Myc [68] (Leal and Carnero, Unpublished results).
The retinoblastoma tumor suppressor pathway, pRb, has
also been related to senescence (Figure 1). Overexpression of
pRb, as well as some of the regulators of the pRb pathway
such as CDK inhibitors, leads to growth arrest mimicking
the senescent phenotype [26]. Moreover, inactivation of pRb
by viral oncoproteins such as E7, SV40 large T antigen, and
E1A leads to extension of lifespan [69–71]. Other members
of the pocket protein family comprising pRb, p130, and p107
may also be involved. In MEFs, p130 levels decrease with
population doublings and MEFs from triple pRb, p130, and
p107 knockout mice are immortal [72]. Nevertheless, since a
certain degree of complementation has been observed among
the pocket protein family [72], it is diﬃcult to assess the role
of each protein in replicative senescence.
Given that p16INK4a functions to inhibit the inactiva-
tion of pRb by CDKs [73], a loss of functional p16INK4a
may be expected to have similar consequences with the loss
of functional pRb. Several types of human cells accumulate
p16INK4a protein as they approach senescence [74]. Senes-
cent fibroblasts may contain p16INK4a levels at least 40-fold
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Figure 1: Scheme representing the senescence eﬀector pathways
crosstalk.
greater than early passage cells. The deletion of p16INK4a
is common in immortalised tumor cell lines [75], and
several nontumorigenic in vitro immortalised cell lines also
lack functional p16INK4a protein. Expression of p16INK4a-
specific antisense in naı¨ve MEFs increases the probability
of immortalisation of these cells [64]. In accordance with
this observation, mice cells which are made nullizygous
for p16INK4a by targeted deletion undergo immortalisation
more readily than normal control cells [76, 77] although
they show normal senescence kinetics. Knockout mice for
p16INK4a proteins develop normally to adulthood and are
fertile, indicating that the individual INK4 proteins are not
essential for development. p16INK4a deficiency, however,
results in a low susceptibility to spontaneous tumor devel-
opment and increased tumor susceptibility under specific
carcinogenic protocols [76, 77]. A crosstalk among the
diﬀerent pathways involved in senescence has been found.
This crosstalk might ensure the correct functioning of the
senescence program. Moreover, genes such as myc that are
involved in all the pathways are able to bypass senescence
in human primary cells. Myc can bypass CDK4/6 inhibition
by activating CDK2-cyclinA/E complexes and inducing the
Cdk-activating phosphatase Cdc25A [78]. Moreover, myc
induces degradation of p27, thus influencing the inhibitory
eﬀects of PTEN. Finally, expression of myc induces telom-
erase activity by activating the transcription of the catalytic
subunit [79]. The overall result is a single step immortalisa-
tion of human cells induced by myc gene amplification [80].
Over all steps, DNA methylation regulates expression
of senescence genes, with the capability of controlling the
process [44]. In human cancers, the silencing of tumour
suppressor genes through aberrant DNA methylation of the
CpG island(s) in promoters in these genes is a common
epigenetic change [81]. There are an assortment of pathways
from which genes have been shown to be hypermethylated
in cancer cells, including DNA repair, cell-cycle control,
invasion, and metastasis. The tumour suppressor genes
BRCA1, p16INK4a, p15INK4b, p14ARF, p73, and APC are
among those silenced by hypermethylation although the
frequency of aberrant methylation is somewhat tumour-
type specific. Recently, we found S-adenosylhomocysteine
hydrolase (SAHH) [46], which has also been previously
identified in an independent short hairpin RNA (shRNA)
screening [82], the inactivation of which confers resis-
tance to both p53- and p16(INK4)-induced proliferation
arrest and senescence. SAHH catalyzes the hydrolysis of
S-adenosylhomocysteine to adenosine and homocysteine.
In eukaryotes, this is the major route for disposal of S-
adenosylhomocysteine formed as a common product of
each of the many S-adenosylmethionine-dependent methyl-
transferases, therefore, regulating the methylation processes.
Interestingly, SAHH inactivation inhibits p53 transcriptional
activity and impairs DNA-damage-induced transcription of
p21(Cip1). SAHH messenger RNA (mRNA) was lost in 50%
of tumour tissues from 206 patients with diﬀerent kinds of
tumours in comparison with normal tissue counterparts.
Moreover, SAHH protein was also aﬀected in some colon
cancers [46, 47].
3. Clinical Implications
The implication of senescence as a barrier to tumorigenesis
first comes from the realisation that a limited number of
duplications necessarily reduces the possibility of tumor
growth. However, the proliferative lifespan before reaching
the Hayflick limit could be suﬃcient to generate a tumor
mass greater than that required for lethality. This argument
fails to take into account the existence of ongoing cell death
and diﬀerentiation within a tumor and the occurrence of
clonal selection driven by diﬀerent senescence barriers or
barriers unrelated to senescence. Finally, a clinically signifi-
cant cancer can be composed of entirely mortal, presenescent
cells if the cell of origin has a suﬃcient proliferative lifespan,
and the tumor develops with few successive clonal expansion
steps and/or with a low cell death rate. Even with these
examples, however, senescence may of course still be a
significant barrier to the recurrence of tumors from the small
number of residual cells remaining after therapy.
As mentioned, several studies in vivo show that
oncogene-induced senescence provides a bona-fide barrier
to tumorigenesis. Michaloglou and coworkers [83] have
shown that an oncogenic BRaf can induce senescence in
fibroblasts and melanocytes and that human nevi display
markers of senescence. Therefore, sustained exposure of
melanocytes to aberrant mitotic stimuli provokes senescence
after an initial proliferation burst. Collado and coworkers
[84] identified senescent cells in vivo after generating new
Journal of Aging Research 5
senescence biomarkers from array studies. Using conditional
Kras-val12 mice strains, they observed senescence markers
to be predominant in premalignant lesions of the lung
and pancreas, but not in those that have progressed to
full-blown cancers. Direct evidence that hyperproliferative
signals can trigger a program of permanent arrest in vivo
have been provided in a transgenic model conditionally
expressing E2F3 in the pituitary gland [85]. E2F3 induced
hyperplasias that failed to progress because the cells became
insensitive to further mitogenic signals. This insensitivity
correlated with the appearance of senescence markers and
a terminally arrested cellular state. Disruption of PTEN in
mice also produces hyperplastic conditions analogous to
prostatic intraepithelial neoplasia (a precancerous lesion in
men). These lesions display senescence markers [86]. Loss of
p53 prevents senescence in response to PTEN ablation and
cooperates to produce invasive prostate carcinomas. These
results are consistent with the notion that senescence actively
limits malignant conversion.
In human fibroblasts in culture, the senescence program
involves chromatin reorganisation involving H3 methylation
at the Lys9 residue concomitant with the recruitment of het-
erochromatin proteins to some proliferation-related genes.
Braig and coworkers [87] found that disruption of Suv39h1
methyltransferase, which methylates the Lys9 residue of H3,
blocked ras-induced senescence and accelerated ras-induced
lymphomagenesis in mice. Interestingly, Suv39h1-expressing
tumors responded through senescence to chemotherapy;
however, Suv39h1-null tumors did not show any senes-
cent response but still maintained the apoptotic response.
Treating ras transgenic mice with DNA-methyltransferase or
histone deacetylase inhibitors, which mimic the eﬀects of
Suv39h1 disruption, accelerated ras-induced tumorigenesis.
The concept of cancer being a disease whereby cells
have lost the ability to senesce leads to a critical evaluation
of the benefits that can be achieved for cancer diagnosis,
and therapy through the knowledge surrounding molecular
pathways (both genetic and epigenetic in origin) that induce
senescence. Until just a few years ago, it was accepted that
tumor cells were no longer capable of senescence. Today,
however, it is accepted that neoplastic cells can be forced
to undergo senescence by genetic manipulations and by
epigenetic factors, including anticancer drugs, radiation,
and diﬀerentiating agents [26, 88]. However, although not
fully studied in vivo, it has been shown that senescent
cells might increase the oncogenic potential of tumor cells.
Therefore, it will be necessary to understand the contribution
of senescent stromal cells to tumors, before applying drug-
induced senescence program to tumors.
Immortalising defects are recessive and can be blocked
by imposing the process of senescence [89]. The first
approach to inducing senescence to tumor cells was through
somatic cell fusion. These studies identified four senescence-
determining complementation groups. In recent years, it has
been found that diﬀerent tumoral cell lines show cellular
growth arrest along with senescence markers after the genetic
expression of tumor suppressor genes commonly involved
in senescence, such as p53, p21, p16, pRb, or p21 [90].
Similarly, the restoration of cellular levels of p53 in a cell
line conditionally immortalised by p53 antisense expression
induces growth arrest with a senescent phenotype [91].
Adenovirus vectors carrying CKIs (p16INK4a, p15INK4b,
p21cip1, and p27kip1) as vehicles for delivery and expression
are a powerful approach to examining therapeutic appli-
cations both in vitro and in vivo, with promising results
[92]. When a 16-amino acid transmembrane carrier segment
derived from theDrosophila antenappedia protein was linked
to the third ankyrin repeat of the p16INK4a protein and
inserted into cells, Rb-dependent G1 arrest was observed.
In a breast-derived cell line, the chimera containing the
antennapedia peptide and the carboxyl-terminal residue of
p21waf1 had higher specificity for CDK4/cyclin D than for
CDK2/cyclin E and arrested the cells in G1 phase [93].
These observations indicate that tumor cells maintain at
least some of the components of the cellular senescence pro-
gram, including terminal growth arrest. It is now clear that
depending upon the cell proliferation kinetics of the tissue of
origin, tumor development can be initiated by genetic events,
causing either a block in terminal diﬀerentiation or/and
inappropriate activation of growth stimulatory signaling
pathways. The net result in both cases is the generation of
a cellular clone capable of infinite expansion if it is not
constrained by physical barriers or lack of blood supply.
Schmitt and collaborators [94] convincingly showed that in a
lymphoidmouse tumormodel, an intact senescence pathway
appears to be pivotal to the eﬃcacy of cyclophosphamide,
and its disruption makes tumor cells highly refractory to the
drug. On the other hand, as mentioned, Suv39h1-expressing
tumors responded to chemotherapy by inducing senescence.
However, Suv39h1-null tumors did not show any senes-
cent response but still maintained the apoptotic response.
Suv39h1-null tumors with altered apoptotic response do not
respond to therapy.
These results suggest that drug eﬃcacy and tumor
formation are not fully independent processes. Until recently,
tumor formation and the development of drug resistance
were thought to be independent processes. Mutations in
factors that regulate tumor-suppressive fail-safemechanisms,
such as apoptosis and senescence, allow transformation.
Chemotherapeutic compounds activate a separate set of
eﬀector pathways that eliminate malignant clones. Mutations
in factors that are involved in these separate pathways inhibit
the eﬀect of chemotherapy to induce the eﬀector programs to
eliminate the tumors. Consequently, defects in antineoplastic
fail-safe programs, even if required to allow for tumor
formation, do not interfere with the eﬀector program
initiated by therapeutic agents. Nevertheless, preclinical data
have provided evidence that key regulators, such as p53,
participate in tumor prevention and drug action and that
tumor mutations acquired during tumor development also
confer chemoresistance [95]. Therefore, the “joint model”
[96] proposes a functional overlap between the fail-safe
and therapeutic eﬀector programs, such that some of the
mutations that allowed transformation can also confer
chemoresistance by disabling drug eﬀector programs.
The in vitro observation that DNA-damaging agents not
only promote apoptosis but also induce cellular senescence
[97, 98] indicates that genes that control senescence might
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also determine treatment outcome. Using a MYC-driven
mouse lymphoma model, p53 and p16INK4A were recently
shown to control drug-induced senescence in vivo [94].
Drug-treated lymphomas with apoptotic defects were forced
into senescence, and tumors that resumed growth frequently
displayed defects in either p53 or p16INK4A. Importantly,
drug-induced senescence was shown to contribute to long-
term host survival after cancer therapy, as mice bear-
ing lymphomas that were unable to enter senescence in
response to therapy had shorter survival times. Notably,
drug-inducible senescence is not a phenomenon that is
restricted to a mouse lymphoma model, as tissue speci-
mens taken from human breast tumors after chemother-
apy also displayed typical features of cellular senescence
[98].
Depending on the initiating oncogene, transformation
relies on fail-safe defects that disrupt either apoptosis or
senescence. There are a number of reports that drug-
inducible senescence could become detectable only after
apoptosis has been disabled [99]. It is conceivable that
senescence occurs with much slower kinetics, serving as a
“backup” fail-safe program in case the first-line response
is corrupted. This is supported by sequential disruption of
apoptosis- and senescence-controlling genes during tumor
formation and subsequent therapy reported in human
cancers [100, 101].
4. Senescence-Based Therapy
Diﬀerent chemical agents can induce cellular senescence
epigenetically. Treatment of primary cells with H2O2 or
butyrate provokes early senescence [102]. Similar results
were obtained after treatment with high doses of radiation
and other damaging agents [102]. Interestingly, the treat-
ment of diﬀerent tumor cell lines with diﬀerent chemother-
apeutic agents, radiation, or diﬀerentiating agents induces
irreversible growth arrest, with enzymatic and morphologic
changes resembling those occurring during replicative senes-
cence. Moderate doses of doxorubicine induced a senescent
phenotype in 11 out of 14 tumor cell lines analysed,
independently of p53 status [103]. A similar eﬀect has been
observed in lines from human tumors treated with cisplatin
[104], hydroxyurea [105], and bromodeoxyuridine [106]. In
mammary carcinoma cell lines treated in vitro and in vivo
with diﬀerentiating agents, terminal proliferative arrest with
minimal toxicity for normal cells has been observed [107].
The propensity of tumor cells to undergo senescence in
response to diﬀerent kinds of damage induced by commonly
used chemotherapeutic treatments was compared on cell
lines from diﬀerent tumor origins [66]. Under equitoxic
doses, the strongest induction of a senescent phenotype
was observed with DNA-interacting agents (doxorubicin,
aphidicolin, and cisplatin), and the weakest eﬀect was
observed with microtubule-targeting drugs (Taxol and vin-
cristine). A medium response was observed with ionising
radiation, cytarabine, and etoposide. Induction of senescence
by the drugs was dose-dependent and correlated with the
growth arrest observed in the cultures [102, 105–107]. The
drug-induced senescent phenotype in tumor cells was not
associated with telomere shortening and was not prevented
by the expression of telomerase [108].
Drug-induced senescent phenotypes have been con-
firmed in vivo ([94] and references therein). A study from
Poele et al. [98] revealed the correlation between chemother-
apeutic treatment in clinical cancer and the senescence
response. In frozen samples from breast tumors treated
by neoadjuvant chemotherapy (cyclophosphamide, doxoru-
bicin, and 5-fluoracyl), senescent markers were detected in
41% of samples from treated tumors. Normal tissue was
negative, suggesting that the chemotherapy-induced senes-
cence was a specific response of tumor cells. Interestingly,
senescence response was associated with wild-type p53 and
the increased expression of p16. Similarly, in treatment-
induced senescence, murine Eμ-myc lymphoma response
required wild-type p53 and p16 [94].
The Chk2 kinase is a tumor suppressor and key
component of the DNA damage checkpoint response that
encompasses cell-cycle arrest, apoptosis, and DNA repair. It
has also been shown to have a role in replicative senescence
resulting from dysfunctional telomeres. Some of these func-
tions are at least partially exerted through activation of the
p53 transcription factor. High-level expression of Chk2 in
cells with wild-type p53 led to arrested proliferation with
senescent features [109]. These were accompanied by p21
induction, consistent with p53 activation. However, Chk2-
dependent senescence and p21 transcriptional induction
also occurred in p53-defective cells. Small interfering RNA-
mediated knockdown of p21 in p53-defective cells expressing
Chk2 resulted in a decrease in senescent cells. DNA-
damage response is also induced by cytokines, such as
interferons. Sustained treatment with interferon triggers a
p53-dependent senescence program. Interferon-treated cells
accumulated gamma-H2AX foci and phosphorylated forms
of ATM and CHK2. The DNA-damage-signalling pathway
was activated by an increase in reactive oxygen species (ROS)
induced by interferon and was inhibited by the antioxidant
N-acetyl cysteine. RNA interference against ATM inhibited
p53 activity and senescence in response to betainterferon
[110]. It seems that p53 activation is the primary response to
DNA damage, but its absence does not preclude a response
with a senescent phenotype.
Comparable to p53, which functions as a fail-safe
mediator of DNA-damage response, the p16 inhibitor has
been implicated in both response to DNA-damage and con-
trol of stress-induced senescence. Although the molecular
mechanism used by p16 to control not only temporary
but permanent cell-cycle arrest is unclear, p16 responds
to DNA-damage in a delayed manner and appears to be
indispensable for the maintenance of cellular senescence
[94, 98]. A synthetic inhibitor of CDK4, possibly mimicking
the role of p16, produced a DNA-damage-independent form
of senescence in cells lacking p16 expression and inhibited
the growth of tumors in mice. Use of siRNAs to inactivate
the papilomavirus oncoproteins E6 and E7, which deregulate
p53 and pRb, restored cellular senescence in cervical cancer
cells. Introduction of E2 protein, a negative regulator of E6
and E7, induced senescence in almost all cervical carcinoma
cells tested. The eﬀect of E2 was not accompanied by
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telomere shortening, nor was it prevented by telomerase
expression. Induction of senescence by E2 was associated
with p53 stabilisation and strong induction of p21, and it was
prevented by using p21 antisenses [111].
Many observations indicate that p53, p21, and p16,
which regulate cellular senescence, play an important role
in treatment-induced senescence of tumor cells. Since these
genes are commonly lost in human tumors, we can expect
that most human tumors do not respond by undergoing
senescence. However, this is not the case. Chemotherapeutic
drugs induced senescence in p53- and p16-defective tumor
cell lines [107]. in vivo, 20% of tumors undergoing senes-
cence after treatment showed p53 mutations [98]. We have
been able to induce senescence with several chemothera-
peutic drugs in p53-null cells independently of p16 (Moneo
and Carnero, unpublished). We have found that the induced
senescence correlated with p53-independent p21 induction.
Moreover, knockout of p53 or p21 in HCT116 cells decreased
but did not abolish cellular senescence. Hence, p16, p53, and
p21 might acts as positive regulators but are not absolutely
required for this response. Other related tumor suppressors,
such as p63 or p73, could be involved, and their role in drug-
induced senescence should be explored.
Treatment with 6-anilino-5,8-quinoline quinone, a pre-
viously described inhibitor of guanylate cyclase, induced
cellular senescence [112]. Microarray analysis revealed that
this compound induced the Cdk inhibitor p21WAF1 in a
p53-independent manner. Furthermore, p21, though not
p53, was required for inhibition of proliferation by the
drug. The lack of p53 involvement suggests that this
compound acts independently of DNA-damage induction.
Growth inhibition was also observed inmalignantmelanoma
and breast cancer cell lines. Functional inactivation of
the retinoblastoma tumor-suppressor protein converted
6-anilino-5,8quinolinequinone-induced growth arrest into
apoptosis. Tumor cell senescence was also found to be
induced by TGFb and by diﬀerentiating agents including
retinoids. The induction of senescence has been analyzed in
more detail with derivatives of vitamin A, which regulate
cell growth and diﬀerentiation through their eﬀects on gene
expression [113].
A prominent feature of immortal cells is a resistance
to oxidative stress. By contrast, primary cells undergo
senescence when grown for extended periods in tissue
culture or exposed to agents that increase production of
reactive oxygen species. It has been also found that enhanced
glycolysis enables primary mouse cells to avoid senescence by
protecting them from oxidative damage, and that immortal
ES cells have intrinsically high levels of glycolysis [49]. siRNA
downregulation of PGM, an enzyme regulating glycolytic
flux, triggers senescent phenotype recovery in tumor cells.
Therefore, regulation of glycolysis and/or ROS production
might be interesting approaches to the induction of senes-
cence in tumors.
5. Telomerase Inhibitors
Restoration of the limited replicative potential in tumors as
an anticancer therapy has been widely examined through the
targeting of telomerase activity. Early studies indicated that
telomerase activity is absent in somatic tissues and present in
most cancers [114]. It was, therefore, reasonable to suggest
that inhibition of telomerase activity, with a consequent
shortening of telomeres and arrest of cell growth, might be
an eﬀective treatment of cancer.
Several diﬀerent approaches to telomerase inhibition
have been adopted to prevent the multiplication of
neoplastic cells in culture. These have included treatment
of the cells with the alkaloid berberine, transfection with an
antisense vector for the human telomerase RNA component,
introduction of a catalytically inactive, dominant-negative
mutant of human telomerase reverse transcriptase, and low-
level expression of a mutant-template telomerase RNA. All of
the treatments inhibit the multiplication of neoplastic cells
in culture, and those tested also inhibit tumor formation
in mice. It should, however, be noted that the transfection
of neoplastic cells with telomerase-inhibitory vectors was
accomplished either in culture before their inoculation
into mice or (in the case of the antisense RNA) through
daily injections into the growing tumors for 7–14 days. No
attempt was made to assess the long-term systemic injection
of vectors into mice carrying the tumors, leaving the matter
of eﬀects on normal cell function yet to be investigated.
Telomere shortening has been observed in the treated tumor
cells and correlates with inhibition of their proliferation
[115]. The expression of threshold levels of mutant-
template telomerase RNA decreases cell viability despite
the retention of endogenous wild-type telomerase RNA,
wild-type telomerase activity, and unaltered stable telomere
lengths.
One reported advantage of telomerase inhibition as a
cancer chemotherapy was that it was not expected to induce
cancer in normal cells, as telomerase activity is closely
associated with advanced tumors [114]. Knockout of the
gene for the RNA component of telomerase in mice does
not, however, prevent either tumor formation or neoplastic
transformation of cells cultured from such mice [116, 117].
The incidence of spontaneous malignancies is even higher
than that of normal mice [117]. A similarly increased risk of
cancer is found in individuals with the inherited syndrome
dyskeratosis congenita (DKC) that is caused by a mutation in
one of the components of telomerase, such that individuals
with DKC are deficient for telomerase activity [118]. This
increased incidence of cancer is presumably a result of end-
to-end fusion of chromosomes destabilized by inadequate
capping [119]. There is, therefore, the distinct possibility that
systemically introduced inhibition of telomerase in cancer
chemotherapy would increase the frequency of chromosome
aberration and the risk of secondary cancers in normal tissue,
particularly when p53 mutations already exist [120].
The situation became more complicated when it was
found that telomerase activity is present in stem cells and
dividing transit cells of renewing tissues, and even when
cell division is induced in tissues conventionally regarded
as quiescent. Thus, it seems likely that all tissues with cells
able to divide have either ongoing or potential telomerase
activity with a capacity for telomere maintenance during cell
division.
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Treatment of cancer by telomerase inhibition is still
considered potentially valid for several reasons that might
mitigate side eﬀects on normal tissues [121]. One reason
is that telomeres are longer in normal tissues than in most
cancers, and treatment of tumors can be designed to end
before telomere depletion in normal tissues [120]. However,
further studies with this approach must be carried out to
protect renewing tissues, such as intestine, epidermis, and
hematopoietic tissue, in which stem cells and transit cells are
constantly dividing at a high rate.
It is expected that telomerase inhibitors will be developed
that have far fewer side eﬀects than many of the cancer
chemotherapeutic agents that are currently available. Indi-
viduals with DKC show features that include abnormalities
of the skin and nails and eventual failure of proliferation in
the bone marrow, which indicates that telomerase is required
for normal proliferative capacity in these somatic tissues.
Despite this telomerase deficiency, onset of pancytopaenia
in these individuals does not occur until a median age of
10 years, which indicates that it might be relatively safe
to administer telomerase inhibitors continuously for several
years.
Telomerase inhibitors will not be useful, however, for
the minority of tumors that use ALT. In addition, in
telomerase-positive tumors it can be predicted that eﬀective
telomerase inhibitors will exert an extremely strong selection
pressure for the emergence of resistant cells that use the
ALT mechanism. Activation of ALT was not observed in cell-
culture experiments in which telomerase-positive cell lines
were treated with small-molecule inhibitors of telomerase
or dominant-negative TERT mutants [122], indicating that
it is not a high-frequency event. This might be a problem,
however, in clinically significant tumors containing as many
as 1012 cells. Development of ALT inhibitors may, therefore,
be necessary. For tumors that use both telomeremaintenance
mechanisms, treatment might need to be initiated with a
combination of telomerase and ALT inhibitors. Both telom-
erase and ALT must access the telomere, but how this might
be achieved is at present unknown. A further possibility
could be to identify molecular targets for simultaneous
inhibition of both telomere maintenance mechanisms, since
proteins involved in telomerase-based and ALT-mediated
events may overlap.
6. Concluding Remarks
The concept of senescence as a barrier to tumorigenesis,
either by natural replicative limits or as stress-induced senes-
cence leads to a critical evaluation of the benefits that can
be achieved for cancer diagnosis and therapy. It is accepted
that neoplastic cells can be forced to undergo senescence by
genetic manipulations and by epigenetic factors, including
anticancer drugs, radiation, and diﬀerentiating agents. These
senescent features can be imposed even in the absence
of the two functional eﬀector pathways, p53 and pRb.
This lead to speculate the possible benefits of inducing an
unspecific senescence program to stop tumor growth. This
might be of value added to surgery or radiation; however,
possible escape from a yet uncontrolled senescent phenotype
and the unknown eﬀect in vivo of senescent stromal cells
might hamper these eﬀorts. A more controlled induction
of senescence through the knowledge of pathways involved
and targeting specific targets might rend a less profitable but
more valued eﬀort. The use of tools such as oncolytic viruses
driven by telomerase promoters might also work better than
direct inhibition of the protein. However, it is too early
and more research is needed in the basic understanding of
the molecular mechanisms driving the senescence processes
before embarking patients in such therapy.
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